Peptide-based probes for cancer imaging.
Receptors for regulatory peptides are overexpressed in a variety of human cancers. They represent the molecular basis for in vivo imaging with radiolabeled peptide probes. Somatostatin-derived tracers, designed to image the sst2-overexpressing neuroendocrine tumors, have enjoyed almost 2 decades of successful development and extensive clinical applications. More recent developments include second- and third-generation somatostatin analogs, with a broader receptor subtype profile or with antagonistic properties. Emerging tracers for other peptide receptors, including cholecystokinin/gastrin and GLP-1 analogs for neuroendocrine tumors, bombesin and neuropeptide-Y analogs for prostate or breast cancers, or Arg-Gly-Asp peptides for neoangiogenesis labeling, are also in current development. Application fields include both SPECT/CT and PET/CT.
Reubi
Jean Claude
JC
University of Berne, Berne, Switzerland. reubi@pathology.unibe.ch
Maecke
Helmut R
HR
D006801:Humans; D009369:Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000378:metabolism; D018358:Neuroendocrine Tumors / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000378:metabolism; D010455:Peptides / Q000737:chemistry; D011868:Radioisotopes; D011877:Radionuclide Imaging; D013004:Somatostatin / Q000031:analogs & derivatives; D013194:Staining and Labeling / Q000379:methods*
D010455:Peptides; D011868:Radioisotopes; D013004:Somatostatin